5 The choice of plasma-derived clotting factor concentrates
- 1 June 1996
- journal article
- Published by Elsevier in Bailliere's Clinical Haematology
- Vol. 9 (2), 273-290
- https://doi.org/10.1016/s0950-3536(96)80063-1
Abstract
No abstract availableKeywords
This publication has 56 references indexed in Scilit:
- Inhibitors in hemophilia patients: Current status and managementAmerican Journal of Hematology, 1994
- Impact of Replacement Therapy on the Evolution of HIV Infection in HemophiliacsThrombosis and Haemostasis, 1994
- Study of viral safety of Scottish National Blood Transfusion Service factor VIII/IX concentrateTransfusion Medicine, 1993
- Frequency of inhibitor development in haemophiliacs treated with low-purity factor VIIIThe Lancet, 1993
- Human parvovirus B19 infection in hemophiliacs first infused with two high‐purity, virally attenuated factor Vlll concentratesAmerican Journal of Hematology, 1992
- Hepatitis C infection in children with hemophilia A and BBlood, 1991
- Factor IX concentrate versus prothrombin complex concentrate for the treatment of hemophilia B during surgeryTransfusion, 1990
- Properties of a Highly Punified Human Plasma Factor IX:c Therapeutic Concentrate Prepared by Conventional ChromatographyVox Sanguinis, 1989
- Factor VIII:C concentrate purified from plasma using monoclonal antibodies: human studiesBlood, 1989
- ACUTE HEPATITIS B INFECTION AFTER TREATMENT WITH HEAT-INACTIVATED FACTOR VIII CONCENTRATEThe Lancet, 1988